Best Practice
How to foster innovation in a hybrid work environment
We have all experienced traditional brainstorming and ideas generation in the pre-COVID office environment.
Industry leaders have tried to pursue innovation during lockdowns and remote work, and found that videoconferences are not well suited for traditional brainstorming. So what explains these struggles with innovation and what can be done about them?
Recent research suggests that leaders can adopt the best practice of asynchronous virtual brainstorming that is relevant to the new hybrid working model. This method, explained in the podcast, also aims to better balance the personality barriers to traditional brainstorming by accommodating the diversity of behavioural preferences within an organisation.
To gain an innovation advantage in the future of work where hybrid working and cognitive diversity are being embedded in the organisational culture, we need to avoid the tendency to stick to pre-pandemic innovation methodology. Instead, we must adopt new research-based best practices for innovation.
News & Trends - Pharmaceuticals
Heart Week: Uniting patient and cardiologist voices in shaping a new future for patient outcomes
Coinciding with the start of the Heart Week (9 – 12 May), Professor Gemma Figtree, Interventional Cardiologist and Immediate Past […]
MoreNews & Trends - MedTech & Diagnostics
‘It’s a marathon not a sprint’: Industry leaders chart next steps in medtech’s sustainability journey
Ahead of World Environment Day in June, Jane Crowe, Managing Director of Cardinal Health Australia and New Zealand and Pravin […]
MoreNews & Trends - Pharmaceuticals
Vaccination accounts for almost half of mortality decline in infants
Pharma News: Researchers have mapped the impact of vaccines to mark the 50-year anniversary of the Expanded Programme on Immunisation […]
MoreNews & Trends - Pharmaceuticals
AbbVie, Pfizer and Bayer therapies to be considered at upcoming PBAC intracycle meeting
Pharma News: Therapies from AbbVie, Pfizer and Bayer are due to be considered at the Pharmaceutical Benefits Advisory Committee (PBAC) […]
More